Jia Jie Biomedical Co Ltd (4109) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Jia Jie Biomedical Co Ltd (4109) has a cash flow conversion efficiency ratio of 0.000x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$281.00K ≈ $8.85K USD) by net assets (NT$1.68 Billion ≈ $52.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Jia Jie Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Jia Jie Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Jia Jie Biomedical Co Ltd total liabilities for a breakdown of total debt and financial obligations.
Jia Jie Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Jia Jie Biomedical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CANTOURAGE GROUP SE O.N.
F:HIGH
|
N/A |
|
Sarine Technologies Ltd
TA:SARN
|
0.021x |
|
Banswara Syntex Limited
NSE:BANSWRAS
|
0.035x |
|
Zhengye Biotechnology Holding Limited Ordinary Shares
NASDAQ:ZYBT
|
N/A |
|
NH SPAC 5
KQ:215790
|
0.096x |
|
DENARIUS METALS CORP.
F:T7C0
|
N/A |
|
MIRA Pharmaceuticals, Inc. Common Stock
NASDAQ:MIRA
|
-0.145x |
|
Ezwelfare Co Ltd
KQ:090850
|
0.020x |
Annual Cash Flow Conversion Efficiency for Jia Jie Biomedical Co Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of Jia Jie Biomedical Co Ltd from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see 4109 stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.36 Billion ≈ $42.82 Million |
NT$44.35 Million ≈ $1.40 Million |
0.033x | +878.02% |
| 2023-12-31 | NT$1.07 Billion ≈ $33.72 Million |
NT$-4.49 Million ≈ $-141.40K |
-0.004x | +55.86% |
| 2022-12-31 | NT$923.96 Million ≈ $29.11 Million |
NT$-8.78 Million ≈ $-276.56K |
-0.010x | -303.12% |
| 2021-12-31 | NT$934.93 Million ≈ $29.46 Million |
NT$4.37 Million ≈ $137.77K |
0.005x | -84.33% |
| 2020-12-31 | NT$907.97 Million ≈ $28.61 Million |
NT$27.10 Million ≈ $853.80K |
0.030x | -16.07% |
| 2019-12-31 | NT$694.88 Million ≈ $21.89 Million |
NT$24.71 Million ≈ $778.56K |
0.036x | +293.94% |
| 2018-12-31 | NT$714.19 Million ≈ $22.50 Million |
NT$-13.10 Million ≈ $-412.60K |
-0.018x | +6.56% |
| 2017-12-31 | NT$699.60 Million ≈ $22.04 Million |
NT$-13.73 Million ≈ $-432.54K |
-0.020x | +75.32% |
| 2016-12-31 | NT$962.54 Million ≈ $30.33 Million |
NT$-76.54 Million ≈ $-2.41 Million |
-0.080x | -195.08% |
| 2015-12-31 | NT$983.23 Million ≈ $30.98 Million |
NT$82.22 Million ≈ $2.59 Million |
0.084x | -- |
About Jia Jie Biomedical Co Ltd
Jia Jie Biomedical Co., Ltd. produces and sells health foods in Taiwan and Mainland China. It operates through two segments: Nutritional Health Products and Insurance Brokerage. The company engages in the processing, sale, and trading of softshell turtle food; manufacture of dairy products; miscellaneous food manufacturing, such as softshell turtle egg powder capsules, enzyme powder, tortoise jel… Read more